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Abstract
MicroRNAs (miRNAs) are short RNA molecules responsible for post-transcriptional gene silencing by the degradation or
translational inhibition of their target messenger RNAs (mRNAs). This process of gene silencing, known as RNA interference
(RNAi), is mediated by highly conserved Argonaute (Ago) proteins which are the key components of the RNA induced silencing
complex (RISC). In humans, Ago2 is responsible for the endonuclease cleavage of targeted mRNA and it interacts with the mRNA-
binding protein GW182, which is a marker for cytoplasmic foci referred to as GW bodies (GWBs). We demonstrated that the anti-
Ago2 monoclonal antibody 4F9 recognized GWBs in a cell cycle dependent manner and was capable of capturing miRNAs
associated with Ago2. Since Ago2 protein is the effector protein of RNAi, anti-Ago2 monoclonal antibody may be useful in
capturing functional miRNAs.
© 2006 Elsevier B.V. All rights reserved.
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1. Introduction
Post-transcriptional gene silencing or RNA interfer-
ence (RNAi) is a crucial regulatory pathway of eu-
karyotic gene expression that occurs in a wide variety of
organisms (Meister and Tuschl, 2004). One key player
in this pathway is the microRNAs (miRNAs), which are
21 to 24 nucleotide long RNA molecules that bind to
partially complementary sequences within the 3′-
untranslated region of target mRNAs leading to trans-
lation suppression and/or degradation. miRNAs are en-
coded in the genome and are transcribed into primary
miRNA (pri-miRNA) molecules. These pri-miRNAs are
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processed in the nucleus by the RNase III enzyme
Drosha and its partner protein DGCR8 (Gregory et al.,
2004). The resulting miRNA precursors (pre-miRNAs)
are then transported to the cytoplasm by Exportin-5
(Lund et al., 2004). Finally, pre-miRNAs are further
processed by the cytoplasmic RNase III enzyme Dicer,
and the resulting mature miRNAs enter the RISC. The
key components of the RISC complex are Argonaute
(Ago) proteins with molecular masses of approximately
100 kDa and containing PAZ and PIWI domains
(Carmell et al., 2002; Sasaki et al., 2003). Four of
these, Ago1 to Ago4, have been demonstrated to asso-
ciate with miRNAs in humans (Liu et al., 2005b).
However, only Ago2 has been demonstrated to possess
the activity of miRNA-guided mRNA cleavage or
translational inhibition (Meister et al., 2004). Thus,
Ago are the key proteins that mediate miRNA function
and the significance for “free” or non-Ago bound
miRNA subsets is unclear. Furthermore, Ago2 has been
shown to associate with GW182, the 182 kDa mRNA-
binding protein (Eystathioy et al., 2002) and a critical
component of GW bodies (GWBs) (Jakymiw et al.,
2005). GWBs are proposed to be cytoplasmic sites
for mRNA storage and degradation (Eystathioy et al.,
2002), and possible sites for RNAi in mammalian cells
(Jakymiw et al., 2005). GW182 is also reported to be
required for efficient miRNA mediated repression of
mRNA (Liu et al., 2005a). Our recent report showed that
the formation of GWBs is a consequence of miRNA
genesis based on the observation that the inhibition
of miRNA maturation led to disassembly of GWBs
(Pauley et al., 2006). In this study, we describe a
novel Ago2 monoclonal antibody 4F9 capable of
capturing Ago-associated miRNAs in mammalian
cells. This monoclonal antibody may be useful in
characterizing functional subsets of miRNA in different
systems.
2. Materials and methods
2.1. Purified recombinant Ago2 protein
A human Ago2 cDNA encoding the full length of the
Ago2 protein was subcloned into pDEST™17 (Invitro-
gen™, Carlsbad, CA, USA) expression vector. The
recombinant protein was produced in Escherichia coli
BL21 (DE3) and purified using Ni2+ affinity chroma-
tography as per the manufacturer’s instructions (Qiagen,
Valencia, CA, USA). The soluble recombinant protein
was subsequently used in the immunization protocol
and enzyme-linked immunosorbent assay (ELISA)
described below.
2.2. Production of mouse monoclonal antibody to Ago2
We have recently reported that anti-Ago2 autoanti-
bodies are detected in a significant number of patients
with autoantibodies to the Su antigen (Jakymiw et al.,
2006). Anti-Su antibodies have also been described
in mice treated with pristane (2,6,10,14-tetramethyl-
pentade-cane, or TMPD). One of the major antigenic
targets of anti-Su is Ago2 but there are other unidentified
Su antigens including the 200 kDa protein (Jakymiw
et al., 2006). To generate anti-Ago2 antibodies, BALB/cJ
mice were intraperitoneally injected with 0.5ml pristane.
Sera were collected 12 weeks later and screened for anti-
Ago2 antibody using an antigen-capture ELISA as de-
scribed (Satoh et al., 1995). Anti-Ago2 positive mice
were then given an intravenous booster injection of
purified soluble recombinant Ago2 protein in phosphate
buffered saline (PBS) three days prior to the harvest of
spleen cells for hybridoma fusion. The hybridoma cells
were cultured and selected using Dulbecco's modified
Eagle's minimal essential medium that contained 15%
horse serum and hypoxanthine-aminopterin-thymidine.
The production of monoclonal antibodies to Ago2 was
screened by ELISA and indirect immunofluorescence
(IIF) as described below. These studies were approved
by the institutional animal care and use committee of the
University of Florida.
2.3. Enzyme-linked immunosorbent assay
Purified soluble recombinant Ago2 protein was
diluted in PBS to a final concentration of 2 μg/ml and
coated on MaxiSorp™ microtiter plates (Nunc™,
Naperville, IL, USA). Undiluted hybridoma culture
supernatants were initially screened and mouse anti-
Ago2 sera were diluted 1:1000 and used as positive
control. Horseradish peroxidase-conjugated goat anti-
mouse IgG (CALTAG™ Laboratories, Burlingame, CA,
USA) was used at a dilution of 1:2000 and the optical
density (OD) at 405 nm was obtained as described
(Rubin, 1997).
2.4. Immunoprecipitation (IP)
Human K562 cells, HeLa cells, HEp-2 cells, and
murine NIH-3T3 cells were metabolically labeled with
[35S]-methionine (MP Biomedicals, Irvine, CA, USA),
resuspended at 107 cells/ml in 500 mMNaCl NET buffer
(500 mMNaCl, 2 mM EDTA, 50 mM Tris-HCl, pH 7.5)
containing 0.3% Nonidet-P40 and Complete Protease
Cocktail Inhibitors (Roche, Mannheim, Germany),
sonicated for 60 s, and cleared by centrifugation at
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10,000 ×g for 10 min. The full-length human Ago
cDNAs (Agol: clone 30344513, GenBank BC063275:
Ago2: pCMV-SPORT6 kindly provided by Dr. Tom
Hobman, University of Alberta, Edmonton, AB, Canada:
Ago3 clone CS0DB008YP10, GenBank AL522515;
Ago4:clone 4373725, GenBank BF979532) were used
as templates for in vitro transcription and translation
(TnT®, Promega, Madison, WI, USA) in the presence of
[35S]-methionine as described (Jakymiw et al., 2006). In
brief, IP of K562 cell extracts and in vitro translated
products were used in IP reactions by combining 100μl of
a 10% Protein A-Sepharose CL-4B beads (Amersham
Biosciences, Piscataway, NJ, USA) with 100 μl of 4F9
culture supernatant or 5 μl of sera, 500 mM NaCl NET
buffer containing 0.3% NP-40, and the individual
radiolabeled proteins. After 1 h incubation at 4 °C, the
suspension was washed four times in 500 mMNaCl NET
buffer containing NP-40, and eluted in 25 μl sample
buffer. For IP experiments involving TnT products, in vitro
translated radiolabeled Luciferase protein was added to the
IP mix to monitor the specificity of IP reactions.
Immunoprecipitates were analyzed by 10% gel SDS-
PAGE followed by autoradiography (Jakymiw et al.,
2006).
2.5. Indirect immunofluorescence (IIF)
HeLa or HEp-2 cells were cultured as monolayers,
fixed in 4% paraformaldehyde in PBS (pH 7.4) for
10 min, permeabilized in 0.1% Triton X-100 and 0.15%
Saponin in PBS for 10 min, incubated with mouse
monoclonal or human antibodies, washed and subse-
quently detected by Alexa Fluor® 488 or Cy3-con-
jugated goat anti-IgG antibody appropriate for the
species (Invitrogen, Eugene, OR, USA). All of the fixa-
tion, permeabilization and incubation with antibodies
were performed on ice. Nuclei in the cell substrates were
counterstained with 4′,6-diamidino-2-phenylindole
(DAPI) that was included in the VectaShield Hard Set
Mounting Medium (Vector Laboratories, Burlingame,
CA, USA). In addition, monoclonal antibodies were also
analyzed on commercial HEp-2 cell slides (HEp2000,
ImmunoConcepts, Sacramento, CA, USA). Rabbit anti-
phosphohistone H3 was obtained from Upstate Biotech
(Charlottesville, VA, USA) and used at a dilution of
1:300 to monitor cells in late S and G2 phases. Images of
fixed cells were obtained using 63×1.4 NA objectives
on a Zeiss Axiovert 200M microscope. For 8-bit color
images, pixel intensity levels were adjusted using Adobe
Photoshop version 7.0 so that maximal and minimal
values were 0 and 255 in each channel.
2.6. MicroRNA RT-PCR assay
RT-PCR was performed using 20 ng of RNAs isolated
from the Protein A Sepharose and antibody complexes,
and HeLa cell extracts after IP as described above except
using unlabeled cells. The RNAs were isolated from
Protein A beads utilizing the mirVana miRNA Isolation
Kit (Ambion, Austin, TX, USA) which was used accord-
ing to the manufacture's protocol. RT-PCR was per-
formed using the mirVana qRT-PCR miRNA Detection
Kit (Ambion). Briefly, miRNAs were reverse transcribed
by using miRNART Primer (Ambion) incubated at 37 °C
for 30 min and then 95 °C for 10 min. After the RT step,
the miRNA cDNA was amplified using miRNA PCR
Fig. 1. Development of mouse monoclonal anti-Ago2 antibody 4F9. (A) ELISA reactivity of 4F9 with purified soluble recombinant Ago2 protein.
(B) Representative immunoprecipitation analysis of 4F9 reactivity using K562 cell extracts (K562) and in vitro translation product of Ago2
recombinant protein (Ago) both labeled with [35S]-methionine. Immune mouse anti-Ago2 serum (IMS) is used for positive control and normal mouse
serum (NMS) as negative control.
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primers with 3 min initial denaturation at 95 °C, and
followed by 30 cycles of 95 °C for 15 s and 60 °C for
30 s. The PCR products were confirmed using a 3.5%
high resolution agarose gel in Tris-Acetate-EDTA buffer
stained with ethidium bromide.
3. Results and discussion
3.1. Development of anti-Ago2 hybridoma from pristane
treated mice
Intraperitoneal injection of pristane into mice leads to
autoantibody responses analogous to those described in
some human systemic lupus erythematosus sera (Satoh
and Reeves, 1994). Recently, we reported that pristane
injected BALB/cJ mice produce anti-Ago2 autoantibo-
dies and these autoantibodies are also detected in
rheumatic disease sera (Jakymiw et al., 2006). To
further support our initial findings, anti-Ago2 autoanti-
body positive mice were selected for hybridoma
production and ∼800 hybridoma clones were screened
with recombinant Ago2 coated ELISA plates. A single
IgG1κ clone, 4F9, showed strong reactivity with
recombinant Ago2 by ELISA (Fig. 1A). Subcloning
using standard limited dilution cloning was performed
twice over a 3 month period.
Fig. 2. Immunofluorescence analysis of 4F9. (A) Monoclonal 4F9 (green) recognized cytoplasmic foci identified as GW bodies (GWBs) by
costaining with a human index serum known to contain antibodies to anti-Ago2 and GW182 (red). HeLa cells (left panels) were fixed as described in
Methods. HEp-2 cells (right panels) were on commercially prepared slides (ImmunoConcepts Inc). Arrowheads show representative GWBs.
(B) Monoclonal 4F9 showed staining of GWBs in a cell cycle dependent manner. HEp-2 cells were costained with 4F9 (green foci, bottom panels)
and rabbit anti-phosphohistone H3 serum (red, top panels).
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3.2. 4F9 recognized a conserved conformational epitope
To confirm that 4F9 recognized Ago2, IP was
performed using K562 cell extracts and in vitro
translated Ago2 protein both radiolabeled with [35S]-
methionine. A 100 kDa protein that comigrated with the
in vitro translated Ago2 protein as well as the positive
control was IP by the immune mouse anti-Ago2 serum
(IMS, Fig. 1B). In contrast, normal mouse serum (NMS)
did not immunoprecipitate Ago2 from K562 cell
extracts or in vitro translated Ago2. The inability of
4F9 and IMS to immunoprecipitate the in vitro trans-
lated Luciferase product also demonstrated the speci-
ficity of 4F9 and IMS for Ago2. Additionally, 4F9
immunoprecipitated Ago2 from radiolabeled HeLa,
HEp-2 and NIH-3T3 cell extracts (data not shown).
4F9 showed very weak or no reactivity in western blot
analysis using HeLa and HEp-2 cell extracts (data not
shown). Furthermore, epitope mapping was attempted
using sequential overlapping peptides of 15 amino acids
spanning the full-length Ago2 protein synthesized on a
membrane as previously described (Eystathioy et al.,
2003). When 4F9 was applied to the membrane for
immunoblotting, specific reactivity was not detected
(data not shown). Additionally, no specific reactivity for
either mouse or human anti-Ago2 sera was detected with
the Ago2 epitope mapping membrane. Interestingly, this
lack of reactivity with denatured or linear epitopes
exhibited by 4F9 is highly consistent with published data
for human and mouse anti-Ago2 autoantibody (Satoh
et al., 1994). Based on these observations, we concluded
that 4F9 recognized a conformational dependent epitope
similar to autoantibody reported for Ago2.
3.3. 4F9 recognized GWBs in a cell cycle dependent
pattern
4F9 recognized cytoplasmic foci identified as
GWBs because there was costaining with a human
index serum known to contain antibodies to Ago2 and
GW182 (Fig. 2A); the latter is a marker protein for
GWBs. This staining pattern was confirmed using both
HeLa cells fixed and permeabilized as described in
Methods and the commercially prepared HEp-2 cells.
To determine optimal fixation parameters, various fixa-
tion methods that included methanol, acetone/metha-
nol, and ethanol were used but none of these retained
the 4F9 staining although GWB staining was clearly
detected (data not shown).
As shown in Fig. 2B, 4F9 staining of GWBs was cell
cycle dependent. By costaining with rabbit anti-
phosphohistone H3 antibody, 4F9 staining was consis-
tent with the reported staining for GWBs, i.e. larger size
during late S and G2 phases of the cell cycle and
diminished staining during mitosis and G1 (Yang et al.,
2004). Since Ago2 is a key component of RISC, the
observation that Ago2 staining is cell cycle dependent
suggests the possibility that Ago2 and GW182/GWBs
may be involved in controlling expression and/or
silencing of selected mRNAs involved in the cell
cycle (Liu et al., 2005a).
Fig. 3. Monoclonal 4F9 crossreacted with Ago1, Ago3 and Ago4. Immunoprecipitation analysis of 4F9 was performed using in vitro translation
products of Ago1, 3 and 4 recombinant proteins labeled with [35S]-methionine. IMS and mouse anti-golgin-97 antibody were used as positive and
negative control, respectively.
Fig. 4. Argonaute monoclonal antibody captured microRNAs.
MicroRNAs were detected in the immunoprecipitates of 4F9 and
IMS using RT-PCR. Immunoprecipitates of an unrelated mouse
monoclonal anti-golgin-97 were analyzed as a negative control. Total
RNAs isolated from human heart were used as a positive control for
the RT-PCR.
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3.4. All Ago proteins could be recognized by 4F9
Mouse and human anti-Ago2 sera reacted not only
with Ago2 but also with Ago1, 3, 4 (Jakymiw et al.,
2006). Consequently, we performed IP analysis of 4F9
using in vitro translated Ago proteins. 4F9 immunopre-
cipitated all Ago proteins as did a mouse anti-Ago2
serum (IMS, Fig. 3). The human Ago proteins have 77.6
to 83.6% sequence identity with each other (Sasaki
et al., 2003) and 4F9 most likely recognizes a shared
conformational epitope found in all Ago proteins. In
addition, it was previously reported that all 4 Ago pro-
teins localized to GWBs (Liu et al., 2005b). Taken
together, we concluded that 4F9 binds all Ago proteins.
3.5. 4F9 captures miRNAs
As discussed above, Ago proteins are known to bind
miRNAs and we speculated that unless 4F9 binds to the
RNA binding domain of Ago proteins and blocks the
interaction of miRNA with Ago, the monoclonal anti-
body may be useful in capturing cellular miRNA bound
to Ago proteins. In order to evaluate whether miRNAs
are co-precipitated with Ago proteins from HeLa cell
extracts, miRNA RT-PCR was performed on the im-
munoprecipitates of 4F9, mouse anti-Ago2 serum and
an unrelated control mouse monoclonal antibody to the
Golgi protein golgin-97. Total RNAs from human heart
were used as a positive control for the RT-PCR. After
miRNA RT-PCR, microRNA-16 (miR-16), microRNA-
24 (miR-24) and let-7a were detected in both 4F9 and
IMS immunoprecipitates but not in anti-golgin-97 im-
munoprecipitates (Fig. 4). In addition, a human anti-
nRNP/Sm serum and a human anti-SS-A/Ro serum were
used as unrelated antibody control for miRNAs capture
and no miRNAs were detected in the immunoprecipitate
using these human anti-ribonucleoprotein sera (data not
shown). These results are consistent with a previous
report that Ago proteins, especially Ago2 protein, and
miRNAs form ribonucleoprotein complexes (miRNPs)
(Meister et al., 2004). The three miRNAs chosen in this
assay have a wide variety of biological functions. miR-
16 and let-7a regulate tumor necrosis factor-α (Jing et al.,
2005) and Ras (Johnson et al., 2005; Akao et al., 2006),
respectively, and miR-24 is related to the regulation of
cell growth (Cheng et al., 2005).
Among the several hundreds human miRNAs iden-
tified to date (Bentwich et al., 2005; Griffiths-Jones et al.,
2006), only relatively few have known biological acti-
vities. The continuing discovery of novel small RNA
such as the class characterized by 26-31 nucleotides and
containing “piwi-interacting RNAs”, or piRNA, impli-
cated in spermatogenesis (Aravin et al., 2006; Girard
et al., 2006; Grivna et al., 2006; Lau et al., 2006;
Watanabe et al., 2006) will increase the need for im-
provements in differentiating miRNAs from other small
RNAs. In summary, we developed a novel monoclonal
antibody 4F9 with the capability of capturing Ago-asso-
ciated miRNAs in mammalian cells and may help to
elucidate their target mRNAs.
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